Kaisha Group plans foray into pharma space in six months
Shapoorji Pallonji Mistry and Kairus Dadachanjii-led Kaisha Group, which recently exited the joint venture with German speciality glass company Schott, is looking to launch its own pharma products in around six months.
Kaisha Group has several companies under its umbrella — Kaisha Lifesciences, Sovereign Pharma, and Kaisha Packaging — that cover the entire value chain from drug manufacturing to packaging. The Dadachanjis and Mistry now plan to tap the front-end of the pharma value-chain by launching their own brands.
For starters, Kaisha Lifesciences has developed some eight to nine products, most of which are already registered in India.
Rishad Dadachanji, managing director of Kaisha Lifescineces, says that these products are antacids, analgesics and blood
thinners. “We have a 25-member R&D team at Kaisha, and are adding more people. In the past few years, we have invested around ~50 crore or so for product development,” he adds.
The firm is recruiting a sales force and putting up a front-end team. “We target to launch some products in the market in around six months,” Dadachanji says. They plan to start from the Mumbai market before spreading to other geographies.
The reason they exited the Schott joint venture was to focus on their pharmaceutical business.
Kaisha’s products will be manufactured by group firm Sovereign Pharma, which is a contract manufacturer of pharma products like injectables, ampoules, etc. It makes complex products like the antiviral remdesivir that is used to treat Covid-19 patients. Sovereign contract manufactures now for multinationals like Pfizer, Novartis, Mylan apart from Indian pharma.
Dadachanji says they plan to add more production lines to Sovereign Pharma’s plant at Daman.